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Autophagy is an evolutionarily conserved, catabolic process that
involves the entrapment of cytoplasmic components within char-
acteristic vesicles for their delivery to and degradation within
lysosomes. Autophagy is regulated via a group of genes called
AuTophaGy-related genes and is executed at basal levels in virtu-
ally all cells as a homeostatic mechanism for maintaining cellular
integrity. The levels and cargos of autophagy can be modulated in
response to a variety of intra- and extracellular cues to bring
about speciﬁc and selective events. Autophagy is a multifaceted
process and alterations in autophagic signalling pathways are
frequently found in cancer and many other diseases. During
tumour development and in cancer therapy, autophagy has par-
adoxically been reported to have roles in promoting both cell
survival and cell death. In addition, autophagy has been reported
to control other processes relevant to the aetiology of malignant
disease, including oxidative stress, inﬂammation and both
innate and acquired immunity. It is the aim of this review to
describe the molecular basis and the signalling events that con-
trol autophagy in mammalian cells and to summarize the cellular
functions that contribute to tumourigenesis when autophagy is
perturbed.
Introduction
In 1963, de Duve introduced the term autophagy, which is derived from
the Greek words ‘auto’ and ‘phagy’ meaning ‘self’ and ‘eating’, to
describe the occurrence of distinct intracellular, membranous vesicles
that contained degraded cytoplasmic material (1). Since then, autoph-
agy has been characterized as an adaptive, catabolic process that serves
to deliver cytoplasmic proteins and organelles to lysosomes for diges-
tion.Dependingonthe route ofdelivery tothe lysosome,three different
types of autophagy are deﬁned: microautophagy, chaperone-mediated
autophagy and macroautophagy (2). This review solely focuses on
macroautophagy, which is hereafter simply termed autophagy.
Autophagy is orchestrated by a number of highly conserved
AuTophaGy-related genes (ATGs), which were originally identiﬁed in
yeast, with many of these genes having orthologues in mammalian cells
(3,4). In mammalian cells, double-membrane-bound autophagosomes
develop in a multi-step process from a precursor structure called the
phagophore or isolation membrane. Autophagosomes subsequently fuse
with lysosomes to form a degradative, single-membrane-bound vesicle
called an autolysosome. In a process named autophagic lysosome refor-
mation, lysosomes are then re-derived from autolysosomes (5).
The role of autophagy extends beyond the general homeostatic re-
moval, degradation and recycling of damaged proteins and organelles
to many speciﬁc physiological and pathological processes such as
development, immunity, energy homeostasis, cell death, tumourigen-
esis and many more (2). The involvement of autophagy in tumour
development is unquestioned but is at present incompletely under-
stood. Deregulation of autophagy is known to affect many processes
that can control the formation and existence of a cancer cell, but
paradoxes still exist in what we currently understand about the re-
lationship between autophagy and cancer (4,6). This review aims
therefore to describe the molecular control of autophagy and to de-
lineate how the deregulation of autophagy can contribute in context-
speciﬁc ways to the development of cancer.
The molecular basis of autophagic vesicle formation
Autophagy is activated in response to a whole host of stimuli includ-
ing nutrient depletion, hypoxia and activated oncogenes. The majority
of pro-autophagic events converge on the serine/threonine protein
kinase mTOR (MTOR, mammalian/mechanistic target of rapamycin)
(7–9). Another important, nutrient-sensitive entry route to ATG
signalling is the class III phosphatidylinositol 3-kinase complex
(PI3K-III) consisting of hVps34 (PIK3C3, the orthologue of yeast
Vps34), Beclin 1 (yeast Atg6) and p150/hVps35 (PIK3R4; yeast
Vps15) (9,10). Many of the aforementioned ATGs are restricted to
a certain type of autophagy (see above). The ‘core’ autophagic
machinery encompasses only those ATGs that are necessary for
autophagosome formation in all subtypes and these can be divided
into several distinct groups: (i) the unc-51-like kinase 1/2 (ULK1/2)
complex (ii) the multi-spanning membrane protein Atg9, (iii) the
PI3K-III complex and (iv) the ubiquitin-like ATG12 and microtu-
bule-associated protein 1 light chain 3 alpha (MAP1LC3A) conjuga-
tion systems. The following sections detail how these proteins
regulate the various stages of the autophagy process.
The autophagy machinery. Initiation and nucleation are terms used
to describe the events that lead to the formation of the initial auto-
phagic structure: the phagophore or isolation membrane. RAPTOR
forms the catalytic subunit of two different protein complexes:
mTORC1 and mTORC2. The former contains mTOR and RAPTOR
(regulatory-associated proteinof MTOR),whereas mTORC2contains
among others, mTOR and RICTOR (rapamycin-insensitive compan-
ion of MTOR) (11). In nutrient-rich states, mTORC1 but not
mTORC2 forms a complex with ULK1/2 (orthologues of yeast
Atg1), mAtg13, FIP200 (RB1CC1; mammalian orthologue of
Atg17) and the newly identiﬁed ATG101, as a result of interaction
between RAPTOR and ULK1 (8,12–14). mTOR phosphorylates
ULK1 and Atg13 and thereby keeps the kinase activity of ULK1 in
check. Upon treatment with rapamycin or in fasting conditions,
mTORC1 breaks free from the ULK complex and the inhibitory
phosphorylation of ULK1 is lost. ULK1 then autophosphorylates
and activates Atg13 and FIP200. The activated ULK complex local-
izes to the developing phagophore. The relationship between mTOR
Abbreviations: ATG, AuTophaGy-related genes; CD, Crohn’s disease;
DRAM1, damage-regulated autophagy modulator 1; ER, endoplasmatic re-
ticulum; LAMP 1/2, lysosomal-associated membrane protein 1/2; MAP1L-
C3A, microtubule-associated protein 1 light chain 3 alpha; MTOR,
mammalian/mechanistic target of rapamycin; PI3K-III, class III phosphati-
dylinositol 3-kinase complex; PtdIns(3)P, phosphatidylinositol 3-phosphate;
ROS, reactive oxygen species; ULK1/2, unc-51-like kinase 1/2; UVRAG,
ultraviolet radiation resistance gene.
 The Author 2011. Published by Oxford University Press.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/
by-nc/2.5), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.and activation of the ULK complex is shown in Figure 1. Startlingly,
the inverse relationship between mTOR activity and autophagy is not
universal,as autophagy induced by 6-thioguanine has been reportedto
require activation and not inhibition of mTOR (15).
There are two mammalian orthologues of Atg9: ATG9L1 (mAtg9) is
ubiquitously expressed, whereas expression of ATG9L2 is restricted
to the placenta and pituitary gland. The exact function of mAtg9
currently remains elusive but it is required for LC3 lipidation and
knockout mice die after birth as do Atg5-a n dAtg7-knockout animals
(16–18).
Phosphatidylinositol 3-phosphate (PtdIns(3)P) is a prerequisite
for the nucleation process. It is produced by the PI3K-III-hVps34
complex when bound to its core partners Beclin 1 and p150/hVps35
(10). The complex is found on the phagophore and thought to facil-
itate recruitment of other ATGs to the developing vesicle. Importantly,
autophagy can be positively and negatively modulated at the level of
the Beclin 1–hVps34–p150/hVps35 complex depending on addi-
tional, regulatory binding partners of Beclin 1 (Figure 1) (4,10).
ATG14/BARKOR (Beclin 1-associated autophagy-related key regu-
lator), UVRAG (protein product of the ultraviolet radiation resistance
gene) and activating molecule in Beclin 1-regulated autophagy are
pro-autophagic regulators of the PI3K-III complex. Simultaneous
binding of both UVRAG and RUBICON (RUN domain and cyste-
ine-rich domain containing) inhibits the autophagy-promoting activ-
ity of the complex (19–23).
Elongation and closure describe the development of the character-
istic double-membrane-bound autophagosome from its precursor
structure and require two ubiquitin-like conjugation systems. The
ubiquitin-like ATG12 is conjugated to ATG5 via the E1-like protein
ATG7 and the E2-like ATG10. ATG16 then enters the complex and
directs the large (L), newly formed ATG16L (ATG12-ATG5-ATG16)
complex to the isolation membrane. The Atg16L complex is required
for autophagosome formation, guides LC3 to the phagophore and
promotes lipidation of LC3 (Figure 1) (24–26).
The ubiquitin-like yeast protein Atg8 has several orthologues in
mammalian cells: MAP1LC3 (LC3), GABARAPL2 (GATE16),
GABARAP and GABARAPL1 (ATG8L). LC3 is the most thoroughly
investigated of these proteins and its modiﬁcation during autophagy is
exploited as a marker for autophagy (27,28). Newly synthesized LC3
is immediately cleaved at its C-terminal end by the protease Atg4 into
the cytoplasmic form LC3-I. If autophagy is active, LC3-I is then
conjugated to phosphatidylethanolamine via ATG7 and the E2-like
ATG3 (29). In its conjugated form, LC3 is called LC3-II and is
recruited via its lipid moiety to the inner and outer surfaces of the
autophagosomal membrane, i.e. unlike LC3-I, LC3-II is not freely
dispersed in the cytoplasm (Figure 1).
The exact order of Atg activation is not clear and there is intensive
crosstalk between the different Atg systems. However, it is generally
accepted that the ULK1 kinase complex and the PI3K-III complex act
upstream of the ubiquitination systems (30).
The maturation process encompasses the fusion of autophagosomes
with lysosomes to form autolysosomes. Autolysosomes are single-
membrane-bound, acidic vesicles comprised of the outer membrane
of autophagosomes and the lysosome that degrade the autophagoso-
mal cargo via acidic hydrolases provided by the lysosome. The pro-
cess is less well understood but involves the action of lysosomal
proteins, such as lysosomal-associated membrane protein 1/2 (LAMP
1/2) and also again, Beclin 1 (3,4).
Work by Yu et al. (5) has recently shed light on the ultimate fate
of autolysosomes. During autophagy-initiation mTOR is inhibited
but becomes reactivated at later stages as a result of the release of
cellular constituents into the cytoplasm following the breakdown of
macromolecules within autolysosomes. Increased mTOR activity
then inhibits autophagy and leads to the formation of proto-lysosomal
extensions (LAMP1þ, LC3 ) from autolysosomes (LAMP1þ,
LC3þ) (30). Ultimately, these proto-lysosomal extensions detach
from the autolysosome and mature into functional lysosomes. Inhibi-
tion of mTOR, or (auto-)lysosomal function, prevents autophagic
lysosome reformation (Figure 2). Autophagy is therefore controlled
by a negative feedback mechanism that is regulated by mTOR (5,30).
Until recently, it was believed that the two ubiquitination systems
are indispensible for autophagy. However, Nishida et al. (31) in-
troduced the term ‘alternative macroautophagy’ to describe a degra-
dative process in response to starvation and etoposide treatment that
involves autophagosome-like structures that are not decorated by
LC3-II. Strikingly, this process is independent of both ATG5 and
ATG7 but critically relies on ULK1 and Beclin 1. Double-membrane-
bound vesicles that included cytoplasmic material were generated
in a RAB9 (RAB9A, member RAS oncogene family)-dependent fash-
ion by the fusion of isolation membranes and vesicles derived from
the trans-Golgi and late endosomes (31). Since this process occurs
without involvement of crucial regulators for ‘conventional’ or ‘ca-
nonical’ autophagy, it is debated whether this phenomenon is some-
thing altogether different from autophagy (32).
Origin of the phagophore/isolation membrane. The ﬁrst detectable
structure during autophagy in mammalian cells is the isolation
membrane or phagophore. Considerable insight has been gained in
the last 2 years in relation to its sites of origin. Current consensus
favours that in mammalian cells, the isolation membrane develops
from at least three different, preformed sources: the endoplasmic
reticulum (ER), the plasma membrane and mitochondria (33–36).
Axe et al. (33) proposed that the phagophore is derived from so-called
omegasomes (cup-shaped protrusions from the ER). Moreover, it
has recently been conﬁrmed that isolation membranes are physically
connected to the ER and are cradled by two ER membranes, which
is reminiscent of the omegasome (37,38). Upon starvation, the
hVps34 kinase is recruited via ATG14L to the ER, where it creates
a local increase in PtdIns(3)P, that is essential for autophagosome
development (39). Proteins that speciﬁcally recognize PtdIns(3)P
Fig. 1. Autophagic core machinery. The ULK kinase complex, the PI3K-III complex, mAtg9 and the two ubiquitination systems are indispensable for autophagy.
Members of the core machinery are shown in coloured boxes. Modulators that are not part of the core machinery are shown in white boxes. For details, see text.
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956are then recruited to the omegasome/cradle, WD repeat domain,
phosphoinositide interacting 2 and ZFYVE1, zinc ﬁnger, FYVE do-
main containing 1, the latter of which can be used to pinpoint the
location of the omegasome/cradle (40,41). The phagophore
extends from the PtdIns(3)P-rich region and is cradled by two ER
membranes (42). Small sections of ER are encapsulated within
autophagosomes by this mechanism. The ULK complex and LC3
localize to the omegasome, as well as the ATG16L complex via
ATG16 (42) (Figure 2).
ATG16L1 has also been reported to be associated with the plasma
membrane (36). This association was mediated by an interaction
between ATG16L1 and the heavy chain of clathrin and it is believed
that this interaction is required for the formation of early autophago-
some precursors (Figure 2). Inhibition of clathrin-mediated internal-
ization reduces the formation of these pre-autophagosomal structures
as well as mature autophagosomes (36). It was proposed by the
authors of this study that due to the size of the plasma membrane,
this source of autophagosomes may be particularly important during
intense autophagic activity (36). A switch may therefore occur from
sources of membrane utilized under basal conditions to the plasma
membrane under stressed conditions in order to perhaps maintain
intracellular organelle integrity.
Mitochondria have also recently been proposed as an alternative
route of phagophore generation (34). Under starving conditions,
ATG5 and LC3 localize to the outer membrane of mitochondria,
which serves as a cornerstone for phagophore development. Mitofusin
2 connects mitochondria to the ER and thereby enables transfer of
phosphatidylserine from the ER to mitochondria, which seems to be
essential for autophagosome generation. In mitochondria, phosphati-
dylserine then gets processed to phosphatidylethanolamine, which
becomes an essential component of the developing autophagosome
as described previously (29). Figure 2 illustrates the development and
recycling of autolysosomes from early precursors and the involve-
ment of the core autophagic machinery in each step.
It seems appropriate to underline that the proposed models of
autophagosome generation are not mutually exclusive and probably
coexist. It is possible that depending on cellular context and activat-
ing triggers, one or all routes are initiated. However, in mammalian
Fig. 2. Autophagic vesicle generation and recycling. The ﬁrst steps of autophagosome formation are initiation and nucleation. The earliest detectable autophagic
structure is the double-membrane-bound phagophore/isolation membrane that evolves from the ER, mitochondria or the plasma membrane following activation of
the ULK1 and Beclin 1 complexes (initiation/nucleation). Subsequently, the ATG16L complex, LC3-II and mAtg9 are recruited to the developing isolation
membrane. The membraneous structure evolves (elongation) and encapsulates marcomolecules to become the closed hallmark structure of autophagy, the
autophagosome. After fusion with a lysosome (maturation), the intra-vesicular constituents of the autophagosome get degraded and released into the cytosol,
thereby creating a local rise in nutrient availability. This leads to reactivation of mTOR and regeneration of a mature lysosome from autolysosomes in a process
called autophagic lysosome regeneration. Members of the core autophagic machinery that are involved in each step and can be found on the corresponding
structure/vesicle are shown in coloured boxes. For details, see text.
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957cells, each model points away from the assembly model (where phag-
ophores develop de novo), unlike in yeast where the phagophore
develops from a phagophore assembly site (43).
Autophagy and cancer
Autophagy is known to protect us against various forms of human
disease (44). In some cases, for example neurodegenerative disease, it
is clear that autophagy facilitates the removal of aggregate-prone
proteins that lead to Huntington’s and Parkinson’s disease (45). The
role of autophagy in cancer, however, is more complex. There is
evidence that autophagy may be oncogenic in some contexts, whereas
in others, it clearly contributes to tumour suppression (4,6,46,47). In
the following sections, we detail the cellular functions, such as in-
ﬂammation, cell death and immunology that may contribute to tu-
mourigenesis when autophagy is impaired and we discuss situations
where dichotomies and paradoxes exist in our understanding of the
role of autophagy in both the genesis and treatment of human cancer.
Numerous studies have described the effects of various speciﬁc onco-
genes and tumour suppressor genes on the rate of autophagy, but due
to the length of this review, these will not be discussed here. For
summaries of these studies, we refer the reader to the following ex-
cellent and extensive recent reviews (4,48).
Links of autophagy to cancer: cell survival, quality control,
inﬂammation and oxidative stress. Cancer is caused by the successive
acquisition of mutations and epigenetic changes that override failsafe
mechanisms such as cell death and cell cycle arrest, which normally
prevent tumour development (49,50). The link between autophagy
and cancer is broad based. Several studies using genetically engi-
neered mice have established a link between autophagy and cancer
development (51–53). For example, hemizygosity of Becn1 (the gene
encoding Beclin 1) or complete loss of the gene encoding
the UVRAG-binding protein BIF-1 (Bax-interacting protein-1, also
known as Endophilin B) results in tumour susceptibility in mice
(51,52,54). In addition, the ectopic expression of Beclin 1 or UVRAG
have both been shown to repress the growth of human cancer cell
xenografts (23,55). In line with these studies, many autophagy genes
have also been found to be inactivated in human cancers (55–59).
Furthermore, both chemotherapy and radiation treatments for cancer
have also been reported to modulate autophagy (60).
Autophagy has an evolutionarily conserved role in buffering
metabolic stress caused by limited nutrients or oxygen. During tu-
mour growth, periods of poor vascularization lead to constraints on
nutrient availability and hypoxic regions within tumours (61). Since
autophagy is known to be activated in these regions and could be
utilized to keep these tumour cells alive, it seems paradoxical there-
fore how inactivation of a process that could keep tumour cells alive
could beneﬁt tumour development. The answer to this apparently
conﬂicting issue simply lies in the basal function of autophagy:
the alleviation of stress in order to preserve cellular integrity (46).
Insufﬁcient autophagy can no longer provide nutrients, prevent the
accumulation of defective proteins and organelles, manage oxidative
stress and limit inﬂammation. As a result intra- and extracellular
events occur that favour malignant transformation.
Autophagy-dependent modulation of cell death and senescence is
critical for tumourigenesis. Perhaps, the largest area in which dichot-
omies exist in relation to autophagy in cancer is in the control of
cell death. For sometime, it has been heavily debated whether autoph-
agy can actually be considered an independent form of programmed
cell death, the so-called type II cell death (62). The Nomenclature
Committee of Cell Death 2009 points out that the latter term ‘may
misleadingly suggest a form of death occurring through autophagy,
as this process often promotes cell survival’ (63). The committee took
a morphological approach to more clearly deﬁne the observations
of many laboratories and proposed the broader description of ‘cell
death occurring with autophagy’ rather than ‘autophagic cell death’
(63). In fact, it is often the case as outlined above that autophagy is
activated to keep cells alive. In many cases, this effect on cell surviv-
al would enhance tumour cell viability and would be tumour pro-
moting, whereas in other cases, the death signals are maybe too
strong for the activated autophagy to counter this effect and the
tumour cell therefore dies—leading to tumour suppression. Criti-
cally therefore, despite being present in these cell death scenarios,
autophagy does not constitute a positive contributing factor towards
cellular demise.
In contrast to its role in cell survival, several studies in Drosophila,
Dictyostelium discoideum and Caenorhabditis elegans have, however,
implicated autophagy as an executor of cell death and not just a mere
co-phenomenon (64–68). To the best of our knowledge, convincing in
vivo evidence that autophagy alone can execute cell death in mam-
malian cells is lacking, even though this possibility is proposed in
several cell culture-based systems (69,70). One view that supports
a role for autophagy in promoting cell death dictates that autophagy
is not an executor of cell death per se but that it is a required process in
certain settings in combination with other pro-death signals. One
important example that may be relevant to cancer is DRAM1 (dam-
age-regulated autophagy modulator 1) (71,72). DRAM1 belongs to
the recently described DRAM family and was identiﬁed due to the
fact that it is activated by DNA damage and the tumour suppressor
p53 (71–73). DRAM1 is a positive modulator of autophagy and is
required for the full execution of p53-induced death. When expressed
alone, however, DRAM1 can modulate autophagy but does not cause
cell death, indicating that autophagy is required but is not sufﬁcient to
bring about this response (71,72).
In addition to the relationship between autophagy and apoptosis,
it is important to note that in many scenarios, autophagy serves to
protect against necrotic cell death with possible detrimental conse-
quences as outlined in subsequent sections (46). Autophagy also pre-
vents anoikis, cell death that occurs after cell detachment from the
extracellular matrix (46,74). Consequently, autophagy may promote
survival of cells that leave their physiological context and could there-
fore represent a mechanism that supports metastasis. Taken together,
autophagy has conﬂicting roles in the regulation of cell death that may
have both positive and negative effects on tumour development.
It is lastly also important to mention the role of autophagy in
senescence. Although not a cell death per se, it is certainly an im-
portant end point in tumour suppression. Senescent cells are marked
by sustained cell arrest and the expression and release of secretory
cytokines that attract the immune system (75). Young et al. (76)
showed that autophagy occurs during senescence and shapes the
senescence-associated secretory phenotype. Impaired autophagy
delayed cytokine production and thereby might modulate the clear-
ance of senescent cells by the immune system.
Autophagy is important for protein and organelle quality control to
prevent cell damage. Autophagy removes injured organelles, mis-
folded and aggregated proteins. If damaged proteins persist, they
are akin to a non-inheritable mutation and are a source of increased
oxidative stress, both of which can have detrimental effects on cells.
Stressed organelles such as the ER also force the cell to execute
adaptive programmes that allow for survival and ultimately promote
tumour growth. Autophagy can therefore be considered to have dual
roles with respect to the management of protein quality control. On
the one hand, the removal of damaged protein and organelles may
promote the survival of tumour cells, whereas on the other hand,
the accumulation of damaged cellular constituents may result in
the production of a hostile cellular environment that may ultimately
be tumour promoting. In this regard, ER stress and the unfolded
protein response are found in, and are required for, a large number
of tumours (77). Impaired autophagy is unable to relieve ER stress
and the resulting unfolded protein response. Therefore, altered signal-
ling persists and potentially causes a reprogramming of the cell,
including nuclear factor-kappaB activation. Kongara et al. (78) also
recently found that defective autophagy itself induces ER stress in
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958mammary cells, which might contribute to the development of breast
cancer in a manner independent of genotoxic stress and genomic
instability. They also underlined the impact of autophagy on the role
of the chaperone protein Sequestome 1/p62 in cancer (see below)
because autophagy-mediated keratin homeostasis is impaired when
p62 levels are altered and keratin is found to be overexpressed in
breast cancer (78).
A-1 Antitrypsin deﬁciency causes chronic liver disease and illus-
trates how insufﬁcient aggregate and organelle removal might
lead to cancer (79). The disease is characterized by the occurrence
of intra-hepatocytic globules that represent large aggregates of a
mutant protein called Alpha-1-antitrypsin (AT) with substitution of
lysine for glutamate at residue 342 within the ER. In affected livers,
autophagy is signiﬁcantly upregulated and responsible for the clear-
ance of aggregates and damaged mitochondria that are injured from
the stressed ER. Possibly, ER accumulation of Alpha-1-antitrypsin
(AT) with substitution of lysine for glutamate at residue 342 induces
the regulator of G signalling 16, which then inhibits the G protein
Gai3 and thereby alleviates Gai3 inhibitory function on autophagy
(79). It is believed that globule-containing cells transmit proliferative
signals to globule-devoid cells that can then grow into adenomas and
carcinomas upon chronic exposure. Furthermore, globule-containing
cells are less proliferative and more resistant to apoptosis (79). Im-
paired autophagy would no longer be able to clear the aggregates and
thus increase the transmission signals of globule-containing cells.
This elevates oxidative damage resulting from injured mitochondria
and increases the pressure to proliferate on globule-devoid cells.
Impaired autophagy shapes the inﬂammatory and immune responses
to assist tumour development. Chronic inﬂammation is thought to be
a risk factor for the development of cancer and many tumours present
with an inﬂammatory component (80). It is believed that autophagy
partly impacts on cancer development through its ability to shape
the inﬂammatory reaction. Orderly removal of dying cells is a vital
function of the organism to prevent undesirable oxidative stress and
an inﬂammatory response that would be triggered from secondary
necrosis. Impaired autophagy causes metabolically stressed and
apoptosis-deﬁcient cells to undergo necrotic cell death (46,61). The
concomitant release of pro-inﬂammatory cytokines thereby creates
a pro-proliferative environment for tumour cells (46,61).
Inﬂammatory bowel disease and pancreatitis are potentially ex-
amples how an underlying defect in autophagy initiates inﬂammation
and thereby creates a pro-tumourigenic environment. Impaired auto-
phagy is found in chronic inﬂammation of the pancreas and the
intestine, both of which are risk factors for the development of cancer
(81). Crohn’s disease (CD) is an inﬂammatory bowel disease that
usually causes transmural inﬂammation of the terminal ileum
(small intestine) but can affect the whole gastrointestinal tract (82).
Mice that are either hypomorphic for Atg16l1 or deﬁcient in either
Atg5 or Atg7 in the intestine display severe cellular abnormalities that
are conﬁned to intestinal Paneth cells and resemble the changes seen
in CD patients that carry the ATG16L1 risk allele (83,84). Paneth cells
have elevated levels of genes involved in peroxisome proliferator-
activated receptor pathways and lipid metabolism (83–85).
ATG16L1-deﬁcient macrophages from chimeric mice (lethally irra-
diated mice with haematopoietic reconstitution from ATG16L1-
deﬁcient foetal liver cells) produce drastically elevated levels of
the inﬂammatory cytokines interleukin-1b and-18 (86). It is tempting
to speculate for a role of autophagy in the development of at least
a subset of intestinal carcinomas because ulcerative colitis, another
inﬂammatory bowel disease, is clearly recognized as a precancerous
lesion, whereas in the case of CD, that relationship is probable but less
clear (87–89).
Development of acute pancreatitis has also been attributed to
retarded autophagy that results from a dysfunction of lysosomal
cathepsins (90). Increased conversion of trypsinogen to trypsin by
Cathepsin B coincides with a decreased action of Cathepsin L that
degrades trypsinogen and trypsin. As a result, intra-acinar trypsin
accumulates, digests surrounding tissue and thereby elicits an
inﬂammatory response (90). Acute pancreatitis precedes chronic
pancreatitis, which is a clear risk factor for the development of
pancreatic carcinoma. CD and pancreatitis might therefore be ex-
amples of how hampered autophagy induces inﬂammation that does
not largely result from necrotic cell death but still contributes to
tumour development.
Autophagy modulates tumour immunology. Autophagy is important
for the balanced execution of the innate and acquired immune
response. Inhibition of autophagy via the PI3K-III inhibitor
3-methyladenine or knockdown of Beclin 1 or ATG12 drastically
reduced the ability of HEK293T (human embryonic kidney cells)
and melanoma cells for presentation of a model antigen or the
endogenous tumour antigen gp100, whereas activation of autophagy
had the opposite effect (91). Defective autophagy therefore poten-
tially promotes tumourigenesis and inﬂammation by constraining
immune recognition of tumour antigens.
T cells participate in inﬂammatory reactions and shape the response
to tumour antigens (92). Autophagy-deﬁcient T cells frequently un-
dergo apoptosis and are less proliferative than autophagy-proﬁcient
cells (93,94). A causative explanation is that they cannot efﬁciently
clear damaged mitochondria and thus have increased reactive oxygen
species (ROS) levels and altered protein expression that favours
pro-apoptotic genes (95,96).
Major histocompatibility complex class II molecules present
antigenic, exogenous proteins on the cell surface of antigen-present-
ing cells and thereby activate CD4þ T-cells. Thymic epithelial cells
require autophagy for proper selection of major histocompatibility
complex-II-restricted antigen recognition i.e. to be able to separate
host from foreign antigens. As a result, impaired autophagy leads to
the production of T cells that recognize host proteins and illicit
a strong inﬂammatory response (97). Epstein–Barr virus is found in
a variety of human tumours, especially lymphoproliferative disorders.
Autophagy-deﬁcient antigen-presenting cells cannot process certain
nuclear viral oncogenes (Epstein–Barr virus-coded nuclear antigen-1)
via the major histocompatibility complex-II pathway, which are there-
fore not present on the cell surface and consequently evade an im-
mune response (98–101).
Oxidative stress is a crucial component of tumourigenesis in stressed
autophagy-deﬁcient cells. The one common denominator of impaired
autophagy in nearly all situations is the creation of oxidative stress.
Oxidative stress results from a disparity between production and
elimination of free radicals and reactive metabolites, so-called ROS.
The mitochondrial respiratory chain is the main source of intracellular
ROS. ROS impact on all stages of tumour formation: initiation, pro-
motion and progression (81). Notably, physiological levels of ROS
are required for many cell signalling events. Physiological concen-
trations of ROS are also critical for autophagy. H2O2 oxidizes and
thereby inhibits Atg4, which leads to increased availability of lipi-
dated LC3 during starvation (102). Cells also use a selective form of
autophagy, mitophagy, to remove damaged mitochondria as a source
of aberrant ROS production. Two molecular routes of mitophagy have
been suggested. phosphatase and tensin homolog-induced kinase 1
recruits the E3 ubiquitin-like ligase PARKIN to compromised mito-
chondria, which results in ubiquitination of voltage-dependent anion
channel 1 on the mitochondrial membrane and recruitment of p62
(103–105). P62 may through its LC3-interacting region steer dam-
aged mitochondria to autophagosomes. Alternatively, mitochondrial
BNIP3L (BCL2/adenovirus E1B 19kDa interacting protein 3-like
(aliases: Nix, BNIP3a)) can via its LC3-interacting region interact
with Atg8 homologues and deliver mitochondria to autophagosomes
(106,107). Furthermore, p62 has also been implicated in the delivery
of oxidized proteins for autophagic degradation. Work from Eileen
White’s group has underlined that management of oxidative stress is
probably the key element how autophagy deﬁciency promotes cancer
(46,61,108–110). It convincingly explains how the loss of a survival
mechanism beneﬁts cancer or in other words it explains why
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959Fig. 3. Cellular and organismal functions that contribute to tumour development when autophagy is impaired. Shown is the impact of autophagy impairment on
crucial cellular processes and how their alteration contributes to tumourigenesis. Importantly, oxidative stress is a recurring phenomenon in nearly all autophagy-
impaired settings. For details, see text.
Fig. 4. Consequences of impaired management of oxidative stress in autophagy-deﬁcient cells. Impaired autophagy results in reduced clearance of p62 and
damagedorganelles,both ofwhich can fuel ROS levels and therebyaggravate oxidativestress. Furthermore,p62 aggregation alters Nf-jB signallingto favour pro-
survival signalling and therefore tumourigenic events. This vicious circle of increased ROS production and decreased clearance of ROS producers and p62
aggregates leadsto geneticinstabilityandan increasedpropensityto mutate DNA. Asa resultof overburdened ROSlevels and DNAdamage,the cells either dieby
necrosis and produce a pro-tumourigenic inﬂammatory response or a subset of cells acquire growth-promoting mutations. For details, see text.
M.T.Rosenfeldt and K.M.Ryan
960autophagy-impaired tumour cells are both more susceptible to cell
death while at the same time havingenhanced tumourigenicity. Figure
3 summarizes how different cellular functions contribute to tumour
formation/progression when autophagy is impaired.
P62 critically links impaired autophagy, oxidative stress and
tumourigenesis. Degenhardt et al. (61) showed that autophagy is
upregulated in hypoxic tumour regions and that autophagy deﬁcien-
cy indeed promotes cell demise but also necrotic cell death. The
resulting, uncontrolled cytokine release creates an inﬂammatory
response and attracts tumour-promoting macrophages. Genomic
stress that leads to DNA damage and an increased propensity to
acquire growth-promoting mutations are cell intrinsic consequences
of insufﬁcient autophagy (109,110). P62 is overexpressed in a
large number of tumours (111). Sequestome-1/p62 is a multi-domain
adapter protein that has emerged as a key player for autophagy-
dependent quality control mechanisms (112). Mice that are deﬁcient
for Atg7 accumulate poly-ubiquitinated aggregates in the liver and
brain that co-localize with p62 and cause cellular damage (113–115).
Mice lacking both p62 and Atg7 are free of aggregates, indicating
that p62 is required for aggregate formation in autophagy-
deﬁcient states and that autophagy is responsible for the clearance
of these aggregates (111,116). In a landmark study, Mathew et al.
(108) showed that p62 is critically required for tumourigenesis, and
depletion of p62 by autophagy suppressed tumour development.
Autophagy-deﬁcient cells are unable to clear p62 aggregates that
arise as a result of metabolic stress. Increased p62 then fuels a detri-
mental positive feedback loop by which p62 itself leads to ROS pro-
duction, enhanced induction of the protein folding machinery in the
ER and a DNA damage response (108). Suppressing ROS or p62
accumulation alleviated cellular damage resulting from impaired au-
tophagy. Strikingly, sustained expression of p62 also altered nuclear
factor-kappaB signalling and thereby initiated additional molecular
pathways that favour tumour formation (108). These data convinc-
ingly imply that the consequences of oxidative DNA damage and
increased tumourigenesis of autophagy-deﬁcient cells are related to
insufﬁcient clearance of p62 (Figure 4).
Summary and therapeutic perspectives
Since it is clear that autophagy has roles in tumour development, it
is natural to speculate if targeting autophagy is a realistic prospect for-
cancer therapy. As evident from this review, one immediate problem
relates to whether we can selectively target the oncogenic role played
byautophagyinkeepingstressedtumourcellsalive,whilenotinhibiting
its role in tumour suppression. It may well be the case that autophagy is
oncogenicatcertainstagesoftumourdevelopmentandtumoursuppres-
sive at other stages and analysis of the role played by autophagy at the
differentstagesofcancerinmousemodelswillcertainlyprovideinsight
intothisissue.Theissue,however,maybeevenmorecomplicatedbythe
fact that the oncogenic and tumour-suppressive effects of autophagy
may coexist not just within one patient but even within any individual
tumour. It must not be forgotten too that autophagy has many beneﬁcial
roles in our normal tissues and in an ideal world it would be best if
autophagy in these contexts was not affected by a systemic therapy
aimed at targeting malignant disease. We consider therefore that
the identiﬁcation of cellular signalling pathways, which selectively
regulate autophagy in response to speciﬁc stimuli, may well hold the
key to the selective targeting of autophagy in human disease. Work in
our own laboratory has sought to address this point with respect to
cancer by searching for signalling pathways that selectively regulate
autophagy in response to hypoxia—a state common in many solid
tumours, but for the most part absent in normal tissue. We found
that autocrine platelet-derived growth factor family signalling—an
event common in cancer—was critical for cytoprotective autophagy
induced by hypoxia but was, in contrast, seemingly dispensable for
autophagy induced by other stimuli (117,118). We feel that our
ﬁndings, therefore, act as a proof of principle paradigm that
disease-associated autophagy could be selectively targeted for ther-
apeutic gain. Ultimately, due to the intense interest in the role of
autophagy in human cancer, it is reasonable to be optimistic that
new studies will lead to important insights into the signiﬁcance of
autophagy in tumour development that will also make targeting
autophagy for cancer therapy a realistic and realizable goal.
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